Clinical Trials Browser

Phase 3 × Epirubicin × 1 year × Clear all

NCT06966700 2026-04-17

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Phase 3 Recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07441460 2026-04-08

A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer

Phase 3 Recruiting

Resectable HER2-positive Breast Cancer

NCT06112379 2026-04-02

A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

Phase 3 Active not recruiting

Breast Neoplasms

NCT07424287 2026-02-20

A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC

Phase 3 Not yet recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT06144944 2026-01-30

Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer

Phase 3 Active not recruiting

Breast Neoplasms

NCT01358877 2025-11-28

APHINITY

Phase 3 Completed

4,804 enrolled 45 charts 2 FDA

Breast Neoplasms

NCT04193059 2025-11-26

PANSY

Phase 3 Active not recruiting

Breast Neoplasms

NCT03036488 2025-10-29

MK-3475-522

Phase 3 Completed

1,174 enrolled 2 FDA

Triple Negative Breast Neoplasms

NCT04335669 2025-09-12

NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC

Phase 3 Active not recruiting

Pathologic Complete Response, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02363400 2025-08-19

A Phase III Trial in NPC With Post-radiation Detectable Plasma EBV DNA

Phase 3 Terminated

Nasopharyngeal Carcinoma, Epstein-Barr Virus Infections

NCT00005584 2025-08-05

Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma

Phase 3 Active not recruiting

Hodgkin Disease, Lymphoma

NCT05862064 2025-07-16

A Multi-center, Randomized, Open-label, Phase III Study Comparing PD-1 Inhibitor Combined With Antivascular Therapy and Anthracycline/Taxane-based Adjuvant Chemotherapy Versus Anthracycline/Taxane-based Adjuvant Chemotherapy Alone in Patients With Operable Triple-negative Breast Cancer

Phase 3 Recruiting

Triple Negative Breast Neoplasms

NCT02455141 2025-07-11

TCTN

Phase 3 Active not recruiting

Breast Neoplasms

NCT03725059 2025-07-11

KEYNOTE-756

Phase 3 Active not recruiting

Breast Neoplasms